Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tick-Borne Encephalitis Remdesivir Efficacy Assessment Trial (TREAT)
2025-523476-23-00Phase 2Authorised
- Sponsor
- Region Stockholm
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in tick-borne encephalitis (TBE) comparing Remdesivir with Placebo (2 arms). Planned start Feb 2026; status: authorised.
02
Drugs
remdesivir
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on 2025-523476-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523476-23-00.